Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HS-10353 in postpartum depression
CTR20231966Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postpartum depression (PPD) comparing HS-10353 with Placebo (2 arms). Primary endpoint: Change from baseline in HAM-D17 total score on Day 15. Started Aug 2024; status: completed.
02
Drugs
HS-10353
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on CTR20231966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231966.